New incident report
Incident Report Number: 2023-1436
Registrant Reference Number: 3563499
Registrant Name (Full Legal Name no abbreviations): Scotts Canada Ltd.
Address: 2000 Argentia Road - Plaza 2 Suite 300
City: Mississauga
Prov / State: ON
Country: Canada
Postal Code: L5N1V8
Human
Country: UNITED STATES
Prov / State: INDIANA
PMRA Registration No. PMRA Submission No. EPA Registration No. 90780-2
Product Name: TOMCAT MOLE KILLER GRUBS
Bait
Yes
Unknown
Site: Res. - Out Home / Rés - à l'ext.maison
No
Data Subject
Sex: Male
Age: >64 yrs / > 64 ans
System
Unknown / Inconnu
Yes
Yes
24
Hour(s) / Heure(s)
Non-occupational
Application
What was the activity? Please refer to field 13 on Subform II or field 17 of subform III for a detailed description regarding the activity
None
Skin
<=15 min / <=15 min
<=30 min / <=30 min
4/3/2023 Consumer is reaching out to report dizziness, malaise, and nausea after a dermal exposure to the TomCat Mole Killer Grubs. On 3/29/2023, he placed the grubs in his yard while not wearing gloves. He was handling them for 5-10 minutes when he suddenly became sick, dizzy, and almost lost his balance. He went inside the house but does not remember if he washed his hands at the time. He started to feel nauseous that night and that his signs and symptoms worsened over the next 2 days. He has not taken anything to manage his signs and symptoms, which he reports at the time of the call have slightly improved. Consumer denies having open wounds on his hands at the time of exposure. 4/7/2023 Follow up with the caller revealed that he sought evaluation for himself at the Emergency Room on 03/30/2023, where he was admitted to the hospital and kept for 24 hours, before being discharged on 03/31/2023. Caller states that while in the hospital he given intravenous fluids, but no other treatments initiated. He was given fluids because providers thought he may have been dehydrated. He also had an magnetic resonance imagining, a computed tomography scan, electrocardiogram, a speech test due to slurred speech, and other "blood tests" that he could not further clarify. All testing came back within normal limits, but he did not provide exact test values. Caller has a history of hypertension, although this was not reported previously. He had been taking Lisinopril for his hypertension, and the hospital changed him to Amlodipine. At the hospital, providers told him that they thought he may have potentially had a stroke, but the testing did not reflect this and no specific diagnosis was provided. Caller was told to follow-up with his primary care provider upon discharge, which he did on 04/03/2023. He had his blood pressure and temperature taken. His temperature came back within normal limits. His blood pressure was slightly elevated, with a reading of 160/80, which was elevated from his baseline of 140/70. Caller was given a prescription for Meclizine from his primary care provider to help with dizziness. Caller was referred to a neurologist for follow-up of symptoms, has yet to make this appointment, but plans to do so today. He has been monitoring his blood sugar at home daily, unclear as to why, and has been receiving results within normal limits. He did not provide exact values, but states results were never over 109. His symptoms are still present at time of report, but continuing to improve. He states that he did not discuss exposure to product with providers at the emergency room or his primary care provider.
Major
The information contained in this report is based on self-reported statements provided to the registrant during telephone Interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and can not form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.